Literature DB >> 21779429

MET Inhibition Results in DNA Breaks and Synergistically Sensitizes Tumor Cells to DNA-Damaging Agents Potentially by Breaching a Damage-Induced Checkpoint Arrest.

Michaela Medová1, Daniel Matthias Aebersold, Wieslawa Blank-Liss, Bruno Streit, Matúš Medo, Stefan Aebi, Yitzhak Zimmer.   

Abstract

While recent studies implicate that signaling through the receptor tyrosine kinase MET protects cancer cells from DNA damage, molecular events linking MET to the DNA damage response machinery are largely unknown. Here, we studied the impact of MET inhibition by the small molecule PHA665752 on cytotoxicity induced by DNA-damaging agents. We demonstrate that PHA665752 reduces clonogenic survival of tumor cells with MET overexpression when combined with ionizing radiation and synergistically cooperates with ionizing radiation or adriamycin to induce apoptosis. In search of mechanisms underlying the observed synergism, we show that PHA665752 alone considerably increases γH2AX levels, indicating the accumulation of double-strand DNA breaks. In addition, PHA665752 treatment results in sustained high levels of γH2AX and phosphorylated ATM postirradiation, strengthening the assumption that MET inhibition attenuates postdamage DNA repair. PHA665752, alone or in combination with irradiation, leads also to a massive increase of γH2AX tyrosine phosphorylation and its subsequent interaction with the proapoptotic kinase JNK1. Finally, MET inhibition reduces activation of ATR, CHK1, and CDC25B and abrogates an associated DNA damage-induced S phase arrest. This indicates that MET inhibition compromises a critical damage-dependent checkpoint that may enable DNA-damaged cells to exit cell cycle arrest before repair is completed.

Entities:  

Keywords:  DNA damage response; MET; PHA665752

Year:  2010        PMID: 21779429      PMCID: PMC3092265          DOI: 10.1177/1947601910388030

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  41 in total

1.  Genomic instability in mice lacking histone H2AX.

Authors:  Arkady Celeste; Simone Petersen; Peter J Romanienko; Oscar Fernandez-Capetillo; Hua Tang Chen; Olga A Sedelnikova; Bernardo Reina-San-Martin; Vincenzo Coppola; Eric Meffre; Michael J Difilippantonio; Christophe Redon; Duane R Pilch; Alexandru Olaru; Michael Eckhaus; R Daniel Camerini-Otero; Lino Tessarollo; Ferenc Livak; Katia Manova; William M Bonner; Michel C Nussenzweig; André Nussenzweig
Journal:  Science       Date:  2002-04-04       Impact factor: 47.728

Review 2.  Genome maintenance mechanisms for preventing cancer.

Authors:  J H Hoeijmakers
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

3.  Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation.

Authors:  D M Aebersold; A Kollar; K T Beer; J Laissue; R H Greiner; V Djonov
Journal:  Int J Cancer       Date:  2001-02-20       Impact factor: 7.396

4.  The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01.

Authors:  P R Graves; L Yu; J K Schwarz; J Gales; E A Sausville; P M O'Connor; H Piwnica-Worms
Journal:  J Biol Chem       Date:  2000-02-25       Impact factor: 5.157

5.  In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis.

Authors:  Roger Abounader; Bachchu Lal; Carey Luddy; Gary Koe; Beverly Davidson; Eliot M Rosen; John Laterra
Journal:  FASEB J       Date:  2001-11-29       Impact factor: 5.191

Review 6.  ATM and related protein kinases: safeguarding genome integrity.

Authors:  Yosef Shiloh
Journal:  Nat Rev Cancer       Date:  2003-03       Impact factor: 60.716

7.  Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy.

Authors:  Kacper Jankowski; Magda Kucia; Marcin Wysoczynski; Ryan Reca; Dongling Zhao; Ela Trzyna; John Trent; Stephen Peiper; Marek Zembala; Janina Ratajczak; Peter Houghton; Anna Janowska-Wieczorek; Mariusz Z Ratajczak
Journal:  Cancer Res       Date:  2003-11-15       Impact factor: 12.701

8.  A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.

Authors:  James G Christensen; Randall Schreck; Jon Burrows; Poonam Kuruganti; Emily Chan; Phuong Le; Jeffrey Chen; Xueyan Wang; Lany Ruslim; Robert Blake; Kenneth E Lipson; John Ramphal; Steven Do; Jingrong J Cui; Julie M Cherrington; Dirk B Mendel
Journal:  Cancer Res       Date:  2003-11-01       Impact factor: 12.701

9.  Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx.

Authors:  Daniel M Aebersold; Olfert Landt; Sylvie Berthou; Günther Gruber; Karl T Beer; Richard H Greiner; Yitzhak Zimmer
Journal:  Oncogene       Date:  2003-11-20       Impact factor: 9.867

10.  Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents.

Authors:  S Fan; J A Wang; R Q Yuan; S Rockwell; J Andres; A Zlatapolskiy; I D Goldberg; E M Rosen
Journal:  Oncogene       Date:  1998-07-16       Impact factor: 9.867

View more
  16 in total

1.  Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.

Authors:  Triparna Sen; Pan Tong; Lixia Diao; Lerong Li; Youhong Fan; Jennifer Hoff; John V Heymach; Jing Wang; Lauren Averett Byers
Journal:  Clin Cancer Res       Date:  2017-07-11       Impact factor: 12.531

Review 2.  MET inhibitors in combination with other therapies in non-small cell lung cancer.

Authors:  Sukhmani Padda; Joel W Neal; Heather A Wakelee
Journal:  Transl Lung Cancer Res       Date:  2012-12

Review 3.  Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy.

Authors:  Vikas Bhardwaj; Tina Cascone; Maria Angelica Cortez; Arya Amini; Jaden Evans; Ritsuko U Komaki; John V Heymach; James W Welsh
Journal:  Cancer       Date:  2013-02-19       Impact factor: 6.860

4.  Crizotinib induces PUMA-dependent apoptosis in colon cancer cells.

Authors:  Xingnan Zheng; Kan He; Lin Zhang; Jian Yu
Journal:  Mol Cancer Ther       Date:  2013-02-20       Impact factor: 6.261

5.  Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer.

Authors:  Avital Lev; Safoora Deihimi; Elena Shagisultanova; Joanne Xiu; Amriti R Lulla; David T Dicker; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2017-09-08       Impact factor: 4.742

6.  c-MET inhibition enhances the response of the colorectal cancer cells to irradiation in vitro and in vivo.

Authors:  Yitao Jia; Guangyao Dai; Jinxi Wang; Xing Gao; Zhaolong Zhao; Zhihui Duan; Bin Gu; Weiguang Yang; Jianhua Wu; Yingchao Ju; Mingxia Wang; Zhongxin Li
Journal:  Oncol Lett       Date:  2016-03-03       Impact factor: 2.967

Review 7.  Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets.

Authors:  Katherine Chang; Anand Karnad; Shujie Zhao; James W Freeman
Journal:  Oncotarget       Date:  2015-02-28

8.  Molecular analysis of the dual targeting of the epidermal growth factor receptor and the O6-methylguanine-DNA methyltransferase with a double arm hybrid molecule.

Authors:  Martin Rupp; Zhor Senhaji Mouhri; Christopher Williams; Bertrand J Jean-Claude
Journal:  Oncotarget       Date:  2018-10-12

9.  The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response-Biological and Clinical Aspects.

Authors:  Michaela Medová; Daniel M Aebersold; Yitzhak Zimmer
Journal:  Cancers (Basel)       Date:  2013-12-19       Impact factor: 6.639

10.  A novel function of hepatocyte growth factor in the activation of checkpoint kinase 1 phosphorylation in colon cancer cells.

Authors:  Na Song; Xiaofang Che; Lu Xu; Jinglei Qu; Huachuan Zheng; Kezuo Hou; Xiujuan Qu; Yunpeng Liu
Journal:  Mol Cell Biochem       Date:  2017-06-01       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.